Freeze-drying protective agent and nucleic acid freeze-drying product and application thereof
By using a specific ratio combination of polyethylene glycol, polyvinylpyrrolidone and polysaccharide, lyophilized microspheres with good stability were prepared, and the unstable lyophilized protective agents in the prior art were solved and the unstable content of animal source components in the high temperature environment in the prior art. The problem is that the stability of the detection microspheres of nucleic acid stored at 50°C and the accuracy of the detection results are achieved.
Patent Information
- Application Number
- CN202411158619.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-08
AI Technical Summary
Existing nucleic acid detection reagents lyophilized protective agents are unstable in high temperature environments, which may lead to atrophy or melting, affecting the accuracy of the detection results, and contain animal-source components to increase production costs and biosafety risks, while also may inhibit polymerase activity and changes. pH value reduces detection sensitivity.
Polyethylene glycol, polyvinylpyrrolidone and polysaccharides (such as trehalose and dextran) are used as lyophilized protection agents. Through a specific ratio combination, lyophilized microspheres with good stability can be prepared, which can be stored at 50°C for 30%. The invariance of the day does not affect the accuracy of the test results.
Provides a freeze-drying protective agent without animal source ingredients, with low production cost and no biosafety risks. The prepared freeze-dried microspheres have stable shape and smooth surface, which can effectively avoid damage to nucleic acid detection substances during lyophilization. Maintain stability at 50°C for 30 days without affecting the subsequent detection effect.
Smart Images

Figure BDA0005005795160000055 
Figure BDA0005005795160000056 
Figure BDA0005005795160000061
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nucleic acid detection, and in particular to a freeze-dried protective agent for nucleic acid detection reagents and a nucleic acid freeze-dried product and use thereof. Background Art
[0002] Nucleic acid testing is an important biomedical research and clinical diagnostic tool used to detect and analyze nucleic acid sequences in biological samples. However, since nucleic acid detection reagents are unstable, they are easily affected by environmental factors such as temperature, humidity, and light, which ultimately affect the accuracy of the test results. In order to solve this problem, researchers usually prepare nucleic acid detection reagents in a freeze-dried form and store them at room temperature to improve their stability. Lyoprotectants are often added during the freeze-drying process. Lyoprotectants are substances that can prevent biological materials from being damaged during the freeze-drying process. They can protect the structure and function of biological materials by forming a glassy state.
[0003] For example, CN110452972B mainly adds a lyophilization protective agent to the nucleic acid detection reagent, and then prepares a lyophilized microsphere reagent through freeze drying technology. This lyophilized microsphere reagent has good stability and can be stored for a long time at room temperature, which greatly improves the convenience and practicality of the nucleic acid detection reagent. At present, the commonly used lyophilization protective agents mainly include mannitol, trehalose, bovine serum albumin, etc.
[0004] Although the existing freeze-dried microsphere reagents have solved the stability problem of nucleic acid detection reagents to a certain extent, there are still some problems and shortcomings. First, the existing freeze-dried protective agents have limited protective effects on nucleic acid detection reagents. For example, the freeze-dried microspheres prepared with the protective agents in CN114317700B and CN114015758B can only be stored at 37°C for more than one month. In the hot summer transportation environment, the temperature usually exceeds 40°C, and the freeze-dried reagents may still shrink or melt in a high temperature environment, affecting the accuracy of the test results. Secondly, most of the existing freeze-dried protective agents contain animal-derived ingredients, such as gelatin, serum, etc., such as the freeze-dried protective agent components in patent CN118028441A, which not only increases production costs, but also may bring biosafety risks. In addition, existing freeze-dried protective agents may have adverse effects on nucleic acid detection reagents, such as inhibiting the activity of polymerases, changing the pH value of reagents, and reducing the detection sensitivity of reagents. Summary of the invention
[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a lyoprotectant and a nucleic acid lyophilized product and use thereof, so as to solve the problems in the prior art.
[0006] To achieve the above objectives and other related objectives, the present invention is achieved through the following technical solutions.
[0007] The first aspect of the present invention provides a lyoprotectant, which comprises polyethylene glycol, polyvinyl pyrrolidone and a polysaccharide.
[0008] Preferably, based on the total mass of the lyophilized protective agent, the content of the polyethylene glycol is 4-40wt%, the content of the polyvinyl pyrrolidone is 4-30wt%, and the content of the polysaccharide is 30-95wt%.
[0009] Preferably, the polysaccharide is selected from one or both of trehalose and dextran.
[0010] Preferably, the polysaccharide is a combination of trehalose and dextran.
[0011] Among them, the selection of polyethylene glycol, polyvinyl pyrrolidone, trehalose and dextran is not random. Only by selecting these four specific substances and cooperating with each other can the freeze-dried microspheres with good stability described in the present application be obtained, which can be stably stored at 50°C for 30 days without changing and will not affect the accuracy of the test results.
[0012] Preferably, based on the total mass of the lyoprotectant, the content of the polyethylene glycol is 4-40wt%, the content of the polyvinyl pyrrolidone is 4-30wt%, the content of the trehalose is 20-60wt%, and the content of the dextran is 4-40wt%.
[0013] For example, the content of polyethylene glycol can be 4.5-36.5wt%, 4.5-40wt%, or 4-36.5wt%; the content of polyvinyl pyrrolidone can be 4.5-28wt%, 4.5-30wt%, or 4-28wt%; the content of trehalose can be 35-55wt%, 35-60wt%, or 20-55wt%; the content of dextran can be 4.5-36.5wt%, 4.5-40wt%, or 4-36.5wt%.
[0014] The range of the above ratio is very important. If the content of polyethylene glycol is too high or polyethylene glycol is not added, cracks or unevenness may appear on the surface of the prepared freeze-dried microspheres (see Formulas 9 and 8 in Comparative Example 2 for details), affecting subsequent applications. If dextran is not added, the thermal stability of the prepared freeze-dried microspheres will be poor (see Formula 5 in Comparative Example 2 for details); if the content of dextran is too high, the prepared freeze-dried microspheres will be damaged (see Formula 11 in Comparative Example 2 for details), affecting subsequent applications; if the content of polyvinyl pyrrolidone is too high, cracks or unevenness may appear on the surface of the prepared freeze-dried microspheres (see Formula 10 in Comparative Example 2 for details), affecting subsequent applications.
[0015] Preferably, the number average molecular weight of the polyethylene glycol is 4000 to 8000, such as 4000 to 6000, 6000 to 8000. The number average molecular weight is obtained by GPC test.
[0016] Preferably, the number average molecular weight of the polyvinyl pyrrolidone is 33000 to 54000, such as 33000 to 40000, 40000 to 54000. The number average molecular weight is obtained by GPC test.
[0017] Preferably, the viscosity of the polyvinyl pyrrolidone at 25° C. is 2.1 to 2.7 mPa·s, such as 2.1 mPa·s, 2.2 mPa·s, 2.3 mPa·s, 2.4 mPa·s, 2.5 mPa·s, 2.6 mPa·s, or 2.7 mPa·s.
[0018] Preferably, the number average molecular weight of the dextran is 450000 to 650000. The number average molecular weight is obtained by GPC test.
[0019] Preferably, the working concentration of the polyethylene glycol is 0.5-4%, w / v, such as 0.5-2%, w / v, 2-4%, w / v.
[0020] Unit: %, w / v, represents the percentage of the mass of the solute to the total volume of the solution, that is, how many grams of solute are contained in every 100 ml of solution. As an example, the working concentration of polyethylene glycol is 4%, w / v, which means that there are 4 grams of polyethylene glycol in every 100 ml of solution.
[0021] Preferably, the working concentration of the polyvinyl pyrrolidone is 0.5-3%, w / v, such as 0.5-1.5%, w / v, 1.5-3%, w / v.
[0022] Preferably, the working concentration of trehalose is 2-6%, w / v, such as 3-6%, w / v, 2-3.5%, w / v.
[0023] Preferably, the working concentration of the dextran is 0.5-4%, w / v, such as 0.5-2%, w / v, 2-4%, w / v.
[0024] The second aspect of the present invention provides a use of the above-mentioned lyoprotectant for preparing a nucleic acid lyophilized product in the field of gene detection.
[0025] The third aspect of the present invention provides a nucleic acid detection kit, which comprises nucleic acid freeze-dried microspheres, and the nucleic acid freeze-dried microspheres contain the lyoprotectant as described above.
[0026] Preferably, the nucleic acid detection kit further comprises one or more of metal salts, dNTPs, dUTPs, primers, probes or enzymes.
[0027] Beneficial effects of the present invention:
[0028] 1) The lyophilized protective agent provided by the technical solution of the present invention does not contain any animal-derived components, has low production costs, and does not pose any biosafety risks.
[0029] 2) The freeze-dried microspheres prepared by adding the freeze-dried protective agent provided by the technical solution of the present invention have a stable morphology, a smooth and bright surface, and meet the subsequent application conditions; and it can not only effectively avoid damage to the nucleic acid detection material during the freeze-drying process, but also will not affect the experimental results of subsequent nucleic acid detection, and there is no adverse effect.
[0030] 3) The lyoprotectant and nucleic acid lyophylline microspheres provided by the technical solution of the present invention have good stability and can be stably stored at 50°C for 30 days without changing their properties, without affecting the accuracy of the test results. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Shown are the packaged freeze-dried microspheres for monkeypox virus nucleic acid detection prepared in Example 2 of the present invention.
[0032] Figure 2 The figure shows the nucleic acid detection performance experimental results of the freeze-dried microspheres for monkeypox virus nucleic acid detection prepared in Example 2 of the present invention.
[0033] Figure 3 The figure shows the stability test results of the freeze-dried microspheres for monkeypox virus nucleic acid detection prepared in Example 2 of the present invention.
[0034] Figure 4 Shown are the packaged freeze-dried microspheres prepared in Example 3 of the present invention for the detection of novel coronavirus nucleic acid.
[0035] Figure 5Shown is one of the graphs showing the results of the stability experiment of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Example 3 of the present invention.
[0036] Figure 6 The second figure shows the stability test results of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Example 3 of the present invention, specifically the quality control chart of the O gene and N gene detection results.
[0037] Figure 7 Shown is the appearance morphology of freeze-dried microspheres for novel coronavirus nucleic acid detection prepared according to Formula 1 of Example 2 of the present invention.
[0038] Figure 8 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Formula 5 of Comparative Example 2 of the present invention.
[0039] Fig. 9 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Formula 6 of Comparative Example 2 of the present invention.
[0040] Fig.10 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Formula 7 of Comparative Example 2 of the present invention.
[0041] Fig.11 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Formula 8 of Comparative Example 2 of the present invention.
[0042] Fig.12 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Formula 9 of Comparative Example 2 of the present invention.
[0043] Fig.13 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in formulation 10 of comparative example 2 of the present invention.
[0044] Fig.14 Shown is the appearance morphology of the freeze-dried microspheres for the detection of novel coronavirus nucleic acid prepared in Formula 11 of Comparative Example 2 of the present invention. DETAILED DESCRIPTION
[0045] The following is a description of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0046] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention. The test methods in the following examples without specifying specific conditions are generally carried out under conventional conditions or under conditions recommended by the manufacturers.
[0047] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0048] In the following embodiments of the present invention, the instruments and equipment used mainly include: ABI7500 fluorescence quantitative PCR detector, freeze dryer, bead machine, vortex mixer, electronic balance, etc.
[0049] The reagents and materials used are:
[0050] 2×TaqMan qPCR mix from finished kit Hieff Universal TaqManmultiplex qPCR master mix was purchased from Yisheng, catalog number 11211ES03.
[0051] 2× V MP Buffer and V Enzyme Mix from the finished kit VMultiplex One Step RT-qPCR Probe Kit (UDG Plus) was purchased from Yisheng, catalog number 13747ES60.
[0052] Trehalose was purchased from Sinopharm, with the national medicine code of 63012666.
[0053] The number average molecular weight of polyvinylpyrrolidone K30 is 40,000 to 54,000.
[0054] The number average molecular weight of dextran is 450,000 to 650,000.
[0055] The number average molecular weight of polyethylene glycol 6000 is 6000.
[0056] Example 1
[0057] This example provides 4 specific freeze-drying protective agent formulations, which are shown in Table 1 below.
[0058] Table 1
[0059]
[0060] The above four lyophilized protective agents were respectively dissolved in 100 ml of water to prepare lyophilized protective agent mother solutions, which were placed at 2-8° C. for standby use. The specific formulas of the four lyophilized protective agent mother solutions are shown in Table 2 below.
[0061] Table 2
[0062]
[0063] Example 2
[0064] This embodiment provides a specific freeze-dried microsphere for monkeypox virus nucleic acid detection, and the preparation process includes the following steps:
[0065] 1) Preparation of monkeypox virus nucleic acid mixture
[0066] Add freeze-dried protective agents of different formulations to the monkeypox virus nucleic acid mixture. The specific formulations are shown in Tables 3 to 6 below. After the preparation is completed, shake and mix well, and place at 2-8°C for use.
[0067] Table 3
[0068]
[0069] Table 4
[0070]
[0071] Table 5
[0072]
[0073]
[0074] Table 6
[0075]
[0076] 2) Preparation of freeze-dried microspheres
[0077] The monkeypox virus nucleic acid mixture prepared in step 1) and added with a lyophilization protective agent is dropped into liquid nitrogen to freeze into round balls, and then freeze-dried using a freeze dryer. The obtained lyophilized microspheres are then divided into eight tubes in a nitrogen-filled isolator and heat-sealed with aluminum foil bags to prevent them from melting due to moisture.
[0078] The packaged lyophilized microspheres are Figure 1 shown.
[0079] The freeze dryer procedure is as follows:
[0080]
[0081] The applicant conducted performance testing on the freeze-dried microspheres prepared in Example 2.
[0082] A) Experimental performance test
[0083] A1) Set up grouping
[0084] Experimental group: Add 20 μL of water to each tube of the above freeze-dried microspheres to redissolve the freeze-dried microspheres, which is used as the experimental group;
[0085] Control group: A mixed solution of monkeypox virus nucleic acid without lyoprotectant was prepared. The formula was exactly the same as that in step 1) except that no lyoprotectant was added and the amount of water added was 8.2 μL.
[0086] 5 μL of plasmid containing monkeypox virus-specific fragments was added to the experimental group and the control group respectively as a reaction template, so that the total reaction system was 25 μL.
[0087] A2) PCR amplification
[0088] The PCR amplification program was as follows: 37°C×2 min; 95°C×90 sec; 95°C×5 sec, 63°C×30 sec, for 42 cycles, with fluorescence detection at 63°C.
[0089] Specific results such as Figure 2 The specific Ct values are shown in Table 7 below.
[0090] Table 7
[0091]
[0092] Depend on Figure 2 As shown in Table 7, compared with the control group, the freeze-dried microspheres with the freeze-dried protective agent had basically no change in detection performance during PCR detection, the Ct value was basically stable, and the detection peaks were basically overlapped. This shows that the addition of the freeze-dried protective agent provided in this example can not only effectively protect the freeze-drying process and prevent the reactants from being damaged during the freeze-drying process, but also will not affect the detection performance of subsequent reagents.
[0093] B) Stability test
[0094] B1) Set up grouping
[0095] Experimental group: The freeze-dried microspheres obtained in Example 2 were placed in a constant temperature test chamber at 25°C, 37°C, 45°C and 50°C for 1 month, as the experimental group;
[0096] Control group: Freshly prepared freeze-dried microspheres were used as the control group.
[0097] 20 μL of plasmid containing monkeypox virus-specific fragments was added to the above experimental group and control group respectively as a reaction template, and the lyophilized microspheres were dissolved before use.
[0098] B2) PCR amplification
[0099] Same as PCR amplification conditions in A2).
[0100] Specific results such as Figure 3 The specific Ct values are shown in Table 8 below.
[0101] Table 8-1
[0102]
[0103] Table 8-2
[0104]
[0105] Depend on Figure 3 As shown in Table 8, compared with the control group, the detection performance of the four groups of monkeypox freeze-dried microsphere reagents was basically unchanged during the PCR detection process after being stored at four temperatures for one month, the Ct value was basically stable, and the detection peak shape was basically coincident. This shows that the addition of the lyophilization protective agent provided in this example can stably store at 50°C for 30 days, and the appearance of the freeze-dried microspheres is still intact, and the performance of the reagent is not affected.
[0106] Example 3
[0107] This embodiment provides a specific freeze-dried microsphere for novel coronavirus nucleic acid detection, and the preparation process includes the following steps:
[0108] 1) Preparation of the novel coronavirus nucleic acid mixture
[0109] Add lyophilized protective agent to the mixed solution for novel coronavirus nucleic acid detection. The specific formula is shown in Table 9 below. After preparation, shake to mix well and place at 2-8℃ for later use.
[0110] Table 9
[0111]
[0112]
[0113] 2) Preparation of freeze-dried microspheres
[0114] Same as step 2 in Example 2).
[0115] The packaged lyophilized microspheres are Figure 4 shown.
[0116] The applicant conducted performance testing on the freeze-dried microspheres prepared in Example 3.
[0117] Set up grouping
[0118] Experimental group: The freeze-dried microspheres were placed in a 50°C test chamber for 4 days, 8 days, 16 days, and 30 days, respectively, as the experimental group;
[0119] Control group: Freshly prepared freeze-dried microspheres were used as the control group.
[0120] 20 μL of plasmid containing the SARS-CoV-2-specific fragment was added to the experimental group and the control group respectively as a reaction template, and the freeze-dried microspheres were dissolved before use.
[0121] Experimental methods
[0122] The freeze-dried microspheres in the experimental group and the control group were tested for sensitivity to the new coronavirus. The minimum detection limit reference (the minimum concentration of a substance that can be accurately detected) was tested, and 8 replicate wells were tested in each group to observe the sensitivity of each group of freeze-dried microspheres.
[0123] The PCR amplification program was as follows: 50°C×3 min; 95°C×90 sec; 95°C×1 sec, 58°C×15 sec, for 45 cycles, with fluorescence detection at 58°C.
[0124] Specific results such as Figure 5 The specific Ct values are shown in Table 10 below.
[0125] Table 10-1
[0126]
[0127]
[0128] Table 10-2
[0129]
[0130] Depend on Figure 5As shown in Table 10, compared with the control group, the new crown freeze-dried microsphere reagent was stored at 50°C for 1 month and used for PCR detection. All 8 test replicates in the experimental group were positive, indicating that the sensitivity of the freeze-dried microsphere reagent in the experimental group was normal and did not change; and the detection performance was basically unchanged, the Ct value was basically stable, and the detection peak shape was basically coincident. This shows that the addition of the freeze-dried protective agent provided in this embodiment can be stably stored at 50°C for 30 days, and the appearance of the freeze-dried microspheres is still intact, and the performance of the reagent is not affected.
[0131] The applicant also determined the mean and upper and lower limits of the O gene and the N gene based on the test data of the existing sensitivity reference, and then drew a quality control chart for the test Ct values after being placed at 50°C for different days (see Table 10 for details). If the test result is between the upper limit (UCL) and the lower limit (LCL), it means that it is within the quality control range, indicating that the freeze-dried microsphere reagent is qualified. The specific results are shown in Figure 6 .
[0132] Depend on Figure 6 It can be seen that after being stored at 50°C for 30 days, the detection results of the O gene and the N gene were still within the quality control range, which means that the new crown freeze-dried microspheres with the addition of the freeze-dried protective agent prepared in this application can remain stable after being stored at 50°C for 30 days, and the performance of the reagent is not affected.
[0133] Comparative Example 1
[0134] This comparative example 1 provides a specific freeze-drying protective agent formula, and the formula is shown in the following Table 11.
[0135] Table 11
[0136]
[0137]
[0138] Note: Formula 5 is exactly the same as Formula 1 except that it does not contain dextran; Formula 6 is exactly the same as Formula 1 except that dextran is replaced by mannitol; Formula 7 is exactly the same as Formula 1 except that dextran is replaced by gelatin; Formula 8 is exactly the same as Formula 1 except that it does not contain polyethylene glycol 6000; Formula 9 is exactly the same as Formula 1 except that polyethylene glycol 6000 is in excess; Formula 10 is exactly the same as Formula 1 except that polyvinylpyrrolidone K30 is in excess; Formula 11 is exactly the same as Formula 1 except that dextran is in excess.
[0139] The above 7 kinds of lyophilized protective agents were dissolved in 100 ml of water respectively to prepare lyophilized protective agent mother solutions, which were placed at 2-8° C. for use. The specific formulas of the 7 kinds of lyophilized protective agent mother solutions are shown in Table 12 below.
[0140] Table 12
[0141]
[0142] Comparative Example 2
[0143] This comparative example provides a specific freeze-dried microsphere for monkeypox virus nucleic acid detection, and the preparation process comprises the following steps:
[0144] 1) Preparation of monkeypox virus nucleic acid mixture
[0145] Comparative freeze-dried protective agents of different formulations were added to the mixed solution for monkeypox virus nucleic acid detection. Except for the different final concentrations (working concentrations) of the freeze-dried protective agents, the rest of the formulations were exactly the same as those in Implementation 2, as shown in Tables 13 to 19. After the preparation was completed, the mixture was shaken and mixed, and placed at 2-8° C. for use.
[0146] Table 13
[0147]
[0148] Table 14
[0149]
[0150] Table 15
[0151]
[0152] Table 16
[0153]
[0154]
[0155] Table 17
[0156]
[0157] Table 18
[0158]
[0159] Table 19
[0160]
[0161] 2) Preparation of freeze-dried microspheres
[0162] Exactly the same as step 2) in Example 2.
[0163] For freeze-dried microsphere reagents, the surface needs to be smooth, shiny, and able to roll. This type of freeze-dried microsphere reagent 1) is not only conducive to subsequent packaging, improving packaging efficiency and reducing operational difficulty; 2) has good physical stability and is not easy to break during storage, transportation, and handling; 3) has good chemical stability and avoids contact with the external environment as much as possible, which is beneficial to the stability of the reagent and the accuracy of the test results. Meet the subsequent application requirements of freeze-dried microsphere reagents.
[0164] If the freeze-dried microsphere reagent has wrinkled, rough, cracked or even damaged surface, in subsequent applications, it is likely that 1) the rehydration rate will be uneven, affecting the stability of the reagent and the accuracy of subsequent experiments; 2) it will also cause the physical properties of the freeze-dried microspheres to deteriorate, making it more likely to be physically damaged during storage, transportation and handling, causing the microspheres to rupture, and thus more susceptible to environmental factors such as external temperature, humidity, and light, which will affect the stability of the reagent and the accuracy of the test results; 3) it will also make it difficult to repack the freeze-dried microspheres, which is not conducive to operation and leads to low work efficiency, etc. The subsequent application requirements of the freeze-dried microsphere reagents are not met.
[0165] The appearance of the freeze-dried microspheres prepared by adding the freeze-drying protective agent of Formula 1 in Example 2 is as follows: Figure 7 As shown;
[0166] The appearance of the freeze-dried microspheres prepared by adding freeze-drying protective agents of Formulas 5 to 11 in this comparative example 2 is as follows Figure 8 to Figure 14 shown.
[0167] Depend on Figure 7 It can be seen that the freeze-dried microspheres prepared using the freeze-dried protective agent of Formula 1 of the present invention have a smooth and shiny surface and can roll, meeting the requirements for subsequent use.
[0168] Depend on Figure 8 It can be seen that the freeze-dried microspheres prepared using the freeze-dried protective agent of Formula 5 of the present invention have a smooth, shiny surface and can roll, which meets the requirements of subsequent use. However, the applicant found that in the subsequent stability test, it can only withstand 37°C and has poor thermal stability.
[0169] Depend on Fig. 9 It can be seen that the freeze-dried microspheres prepared using the freeze-dried protective agent of Formula 6 of the present invention have wrinkles on the surface and are morphologically unstable, resulting in failure to meet the requirements of subsequent applications. The specific reasons are described above.
[0170] Depend on Fig.10 It can be seen that the freeze-dried microspheres prepared using the freeze-dried protective agent of Formula 7 of the present invention have a smooth, shiny surface and can roll, which meets the requirements of subsequent use. However, the applicant found that in the subsequent stability test, it can only withstand 37°C and has poor thermal stability.
[0171] Depend on Fig.11 It can be seen that large cracks appeared in the center of the surface of the freeze-dried microspheres prepared using the freeze-dried protective agent of Formula 8 of the present invention, resulting in failure to meet the requirements of subsequent applications.
[0172] Depend on Fig.12 It can be seen that the surface of the freeze-dried microspheres prepared using the freeze-dried protective agent of Formula 9 of the present invention is not smooth, resulting in failure to meet the requirements of subsequent applications.
[0173] Depend on Fig.13 It can be seen that the freeze-dried microspheres prepared using the freeze-dried protective agent of formula 10 of the present invention have a wrinkled surface and are difficult to roll, resulting in failure to meet the requirements of subsequent applications.
[0174] Depend on Fig.14 It can be seen that the freeze-dried microspheres prepared using the freeze-dried protective agent of formula 11 of the present invention are easily damaged and incomplete, resulting in failure to meet the requirements of subsequent applications.
[0175] In summary, when the lyophilized protective agent provided by the technical solution of the present invention is used to prepare the lyophilized microspheres for nucleic acid detection, the obtained lyophilized microspheres have a stable morphology, a smooth and bright surface, and meet the subsequent application conditions; it can not only prevent the material from being damaged during the freeze-drying process, but also will not affect the performance of the lyophilized microspheres in the subsequent detection process. In addition, the lyophilized microspheres for nucleic acid detection containing lyophilized protective agents provided by the present application have good stability, can be stored at 50°C for 30 days without denaturation, and are suitable for large-scale promotion and application in the field of nucleic acid detection.
[0176] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A freeze-drying protective agent, characterized in that The lyoprotectant comprises polyethylene glycol, polyvinyl pyrrolidone and polysaccharide.
2. The lyoprotectant according to claim 1, characterized in that Based on the total weight of the freeze-dried protective agent, the content of the polyethylene glycol is 4-40wt%, the content of the polyvinyl pyrrolidone is 4-30wt%, and the content of the polysaccharide is 30-95wt%.
3. The lyoprotectant according to claim 1, characterized in that The polysaccharide is selected from one or both of trehalose and dextran.
4. The lyoprotectant according to claim 3, characterized in that The polysaccharide is a combination of trehalose and dextran.
5. The lyoprotectant according to claim 4, characterized in that Based on the total weight of the lyophilized protective agent, the content of the polyethylene glycol is 4-40wt%, the content of the polyvinyl pyrrolidone is 4-30wt%, the content of the trehalose is 20-60wt%, and the content of the dextran is 4-40wt%.
6. The lyoprotectant according to claim 1, characterized in that The number average molecular weight of the polyethylene glycol is 4000 to 8000; And / or, the number average molecular weight of the polyvinyl pyrrolidone is 33000 to 54000; And / or, the viscosity of the polyvinyl pyrrolidone at 25° C. is 2.1 to 2.7 mPa·s.
7. The lyoprotectant according to claim 3, characterized in that The number average molecular weight of the dextran is 450,000-650,000.
8. The lyoprotectant according to claim 3, characterized in that The working concentration of the polyethylene glycol is 0.5-4%. w / v; and / or, the working concentration of the polyvinyl pyrrolidone is 0.5-3%, w / v; and / or, the working concentration of trehalose is 2-6%, w / v; And / or, the working concentration of the dextran is 0.5-4%, w / v.
9. Use of the lyoprotectant according to any one of claims 1 to 8 for preparing freeze-dried nucleic acid products in the field of gene detection.
10. A nucleic acid detection kit, characterized in that: The nucleic acid detection kit comprises nucleic acid freeze-dried microspheres, and the nucleic acid freeze-dried microspheres contain the freeze-dried protective agent according to any one of claims 1 to 8.
